HealthEquity, Inc. (NASDAQ:HQY) is Wasatch Advisors LP’s 2nd Largest Position

Wasatch Advisors LP reduced its stake in HealthEquity, Inc. (NASDAQ:HQY) by 3.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,513,745 shares of the company’s stock after selling 245,145 shares during the period. HealthEquity accounts for 3.6% of Wasatch Advisors LP’s holdings, making the stock its 2nd biggest holding. Wasatch Advisors LP owned about 8.67% of HealthEquity worth $720,944,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of HQY. Arcadia Investment Management Corp MI purchased a new stake in HealthEquity in the fourth quarter worth about $26,000. Smartleaf Asset Management LLC boosted its stake in shares of HealthEquity by 34.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 384 shares of the company’s stock valued at $37,000 after purchasing an additional 98 shares in the last quarter. UMB Bank n.a. increased its holdings in HealthEquity by 65.6% during the fourth quarter. UMB Bank n.a. now owns 414 shares of the company’s stock valued at $40,000 after buying an additional 164 shares during the period. Skandinaviska Enskilda Banken AB publ raised its stake in HealthEquity by 1,934.8% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 468 shares of the company’s stock worth $45,000 after buying an additional 445 shares in the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in HealthEquity by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 750 shares of the company’s stock worth $72,000 after buying an additional 162 shares during the period. 99.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HQY has been the topic of a number of analyst reports. The Goldman Sachs Group cut their price target on HealthEquity from $107.00 to $94.00 and set a “neutral” rating on the stock in a report on Thursday, March 27th. Raymond James upgraded HealthEquity from an “outperform” rating to a “strong-buy” rating and cut their target price for the company from $120.00 to $115.00 in a research note on Tuesday, March 25th. Barrington Research reissued an “outperform” rating and set a $112.00 price target on shares of HealthEquity in a research report on Friday, April 11th. KeyCorp cut their price objective on shares of HealthEquity from $120.00 to $110.00 and set an “overweight” rating on the stock in a research report on Monday, March 24th. Finally, Wells Fargo & Company boosted their price objective on shares of HealthEquity from $110.00 to $125.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $112.58.

HealthEquity Price Performance

Shares of HQY opened at $83.03 on Wednesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.20 and a quick ratio of 3.20. The company’s fifty day moving average price is $96.47 and its 200-day moving average price is $96.35. HealthEquity, Inc. has a 1-year low of $65.01 and a 1-year high of $115.59. The firm has a market capitalization of $7.18 billion, a PE ratio of 76.17, a price-to-earnings-growth ratio of 1.60 and a beta of 0.49.

Insiders Place Their Bets

In related news, EVP Michael Henry Fiore sold 8,881 shares of the stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $78.26, for a total value of $695,027.06. Following the transaction, the executive vice president now owns 56,655 shares in the company, valued at approximately $4,433,820.30. This represents a 13.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert W. Selander sold 5,750 shares of HealthEquity stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $111.29, for a total transaction of $639,917.50. Following the sale, the director now owns 78,219 shares of the company’s stock, valued at approximately $8,704,992.51. The trade was a 6.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 20,381 shares of company stock valued at $1,781,432. 2.20% of the stock is owned by company insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.